NASDAQ · Biotechnology

ZVRA (ZVRA) Stock

$9.56 -1.75% NASDAQ: ZVRA Healthcare

Valuation

MetricValue
Price$9.56
Market Cap$565.14M
P/E Ratio7.56
P/B Ratio3.89
P/S Ratio5.03
EPS (TTM)$1.35
52-Week High$14.75
52-Week Low$7.16
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE53.55%
ROA29.12%
ROCE-2.58%
Gross Margin-4.72%
Operating Margin-3.77%
Net Margin1.02%
Debt/Equity0.01
Current Ratio5.72

Annual Financials (USD)

Metric20212022202320242025
Revenue$29.0M$10.0M$27.0M$24.0M$106.0M
Operating Profit$8.0M$-43.0M$-50.0M$-87.0M$-4.0M
Net Profit$-9.0M$-27.0M$-46.0M$-106.0M$83.0M
EPS$-2.11$-0.78$-1.30$-2.28$1.35
Op Margin27.0%-418.9%-180.6%-368.5%-4.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$133.0M$115.0M$172.0M$178.0M$285.0M
Total Liabilities$6.0M$40.0M$110.0M$138.0M$130.0M
Cash$112.0M$65.0M$43.0M$34.0M$62.0M
Borrowings$2.0M$19.0M$44.0M$60.0M$63.0M

Latest News

Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) GlobeNewswire · Jun 23, 2026 Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition GlobeNewswire · Jun 11, 2026 Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat? Simply Wall St. · Jun 9, 2026 ZVRA Stock Hits Its Highest Levels In Nearly 5 Years – What’s Driving This Sharp Rally Today? Stocktwits · Jun 9, 2026 ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug Stocktwits · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$10.0M$-19.0M$-34.0M$-70.0M$-2.0M
Investing Cash Flow$-16.0M$-37.0M$-18.0M$-22.0M$17.0M
Financing Cash Flow$102.0M$-4.0M$3.0M$1.0M$0
Net Cash Flow$108.0M$-47.0M$-22.0M$-9.0M$29.0M
Free Cash Flow$10.0M$-19.0M$-34.0M$-70.0M$-2.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield1.95%
Quick Ratio4.84
Interest Coverage-0.50
Return 1Y6.37%
Return 3Y162.47%
Return 5Y15.58%

Ownership

Insiders Held1.28%
Institutions Held72.65%
Institutions Float Held73.60%
Institutional HolderSharesReport Date
Woodline Partners LP3,450,9432026-03-31
FMR, LLC3,211,8772026-03-31
Nantahala Capital Management, LLC2,521,9362026-03-31
Vanguard Capital Management LLC2,469,3282026-03-31
State Street Corporation1,561,5692026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AKBA $1.31 -0.76% -45.00 $351.42M 0.00%
CRVS $13.31 +3.02% -23.00 $1.12B 0.00%
GOSSGossamer Bio, Inc. $0.19 +38.24% -0.17 $44.10M 0.00%
KALV $27.00 +0.00% -8.28 $1.44B 0.00%
NAGE $3.12 +2.63% 18.75 $248.49M 0.00%

About ZVRA

ZVRA is led by CEO Neil F. McFarlane, employs 59 people, headquartered in US, publicly traded since 2015.

ZVRA stock trades at $9.56 with a market capitalization of $565.14M. The stock is valued at a price-to-earnings (P/E) ratio of 7.56, price-to-book of 3.89, price-to-sales of 5.03. Over the past 52 weeks the stock has ranged between $7.16 and $14.75, and currently trades 35.2% below its 52-week high.

On profitability, ZVRA generates a return on equity (ROE) of 53.55% — well above the market average, a sign of a high-quality business, return on capital employed of -2.58%, an operating margin of -3.77%, a net profit margin of 1.02%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides